DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Abrilumab
Abrilumab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
ヤンセンファ࣮ч株式会社
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
Anti-Integrin Therapy for Inflammatory Bowel Disease S
Biological Treatments in Inflammatory Bowel Disease: a Complex Mix Of
The Current State of the Art for Biological Therapies and New Small Molecules in Inflammatory Bowel Disease
Stembook 2018.Pdf
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
211 the Impact of Biological Interventions on Health-Related Quality of Life in Adults with Crohn's Disease
New Targets in Inflammatory Bowel Disease Therapy: 2021
Ulcerative Colitis and Probiotics: an Overview
(INN) for Biological and Biotechnological Substances
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
What Science Can Do
Top View
Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease
International Nonproprietary Names for Pharmaceutical Substances (INN)
(12) Patent Application Publication (10) Pub. No.: US 2017/0173267 A1 Ashmead Et Al
Clinical Trials Appendix Q1 2016 Update PDF 2473KB
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
(2006.01) C07d 413/14
Novel and Emerging Therapies for Inflammatory Bowel Disease
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
Efficacy and Safety of Abrilumab, an Α4β7 Integrin Inhibitor, in Japanese Patients with Moderate-To-Severe Ulcerative Colitis: a Phase II Study
Classification of "Voxtalisib" (Inn List 108) And
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
The IBD Therapeutic Pipeline Is Primed to Produce
(INN) for Biological and Biotechnological Substances
WO 2018/231759 Al 20 December 2018 (20.12.2018) W !P O PCT
(INN-Nimet) 8.12.2020
Emerging Therapies for Inflammatory Bowel Disease
2016 Medicines in Development for Autoimmune Diseases
Additional Information PDF 889KB
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Therapeutic Drug Monitoring In